HUA Medicine, an innovative pharmaceutical company, is redefining the treatment paradigm for Type-2 diabetes (T2D) by addressing its underlying causes rather than merely managing symptoms. Headquartered in Shanghai, the company has gained international recognition for its groundbreaking research, which has been featured in esteemed scientific journals. HUA Medicine has successfully developed and commercialized HuaTangNing (dorzagliatin tablets), the first-in-class oral medication designed to restore glucokinase function - an essential enzyme that serves as the body's natural glucose sensor.
In individuals with Type-2 diabetes, glucokinase function is often impaired, disrupting the body's ability to regulate glucose levels effectively. Dorzagliatin restores this critical function, enabling the body to maintain continuous glucose homeostasis, a significant advancement over conventional treatments that rely on frequent blood glucose monitoring, insulin injections, or other pharmaceutical interventions.
“Our mission is ambitious yet unequivocal: to halt the progression of Type-2 diabetes by reinstating the body’s natural ability to regulate glucose autonomously. This principle forms the foundation of HUA Medicine's breakthrough therapy,” states Dr. Li Chen, Founder and CEO.
Extensive research underscores the therapeutic potential of enhancing glucokinase function, with studies indicating that this approach can significantly improve T2D outcomes. Notably, patients have demonstrated the ability to achieve remission or remain drug-free for up to a year following treatment.
HuaTangNing received approval from China’s National Medical Products Administration (NMPA) in September 2022 and was subsequently added to the National Drug Reimbursement List in early 2024, enhancing accessibility and affordability for Chinese T2D patients. By 2024, the medication was available in over 2,100 hospitals and 2,900 pharmacies across China, marking a substantial expansion from the 143 hospitals and 1,080 pharmacies recorded in early 2023.
With a commitment to global accessibility, HUA Medicine is actively working to introduce its innovative therapy to international markets. In late 2024, the company successfully completed a Phase I clinical trial in the United States for a second-generation, once-daily formulation of its glucokinase activator, further advancing its global expansion strategy. Dorzagliatin is also uniquely effective for T2D patients at any stage of chronic kidney disease, including those with end-stage renal disease. It remains the only oral T2D medication available for patients with kidney disease that effectively controls blood glucose without requiring dose adjustments.
Clinical trials have reinforced the efficacy of HUA Medicine’s approach. The DREAM study demonstrated that 65.2% of patients achieved drug-free diabetes remission for 52 weeks following dorzagliatin treatment in a Phase 3 trial. Additionally, the SENSITIZE study, completed in November 2024, confirmed that dorzagliatin effectively restores glucokinase enzyme activity and enhances insulin secretion in patients with impaired glucose tolerance and glucokinase monogenic diabetes.
Guided by its core mission - "For Patients, Global Innovation, Effective Medicines"- HUA Medicine remains dedicated to integrating cutting-edge pharmaceutical research and development. The company aspires to revolutionize diabetes treatment and establish itself as a global leader in metabolic disease innovation.
This documentary is part of Health Heroes, an official series of the Global Health Council, brought to you by Special Interest Films.
#HUAMedicine #HealthHeroes #GlobalHealthCouncil #SpecialInterestFilms #Documentary #Health #HumanHealth #Diabetes #Type2Diabetes #Glucokinase #DiabetesResearch #Innovation #Medication #Science #Biology #Laboratory #YouTube #YouTubeVideo #YouTubeChannel
Информация по комментариям в разработке